| 摘要 |
<p>TCA/PLGA microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. TCA/PLGA microparticle formulations are administered locally as a sustained release dosage form that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous Cortisol production.</p> |
